Supervisory and Management Boards
Supervisory Board
Jonathan Symonds, CBE
Chairperson
Mr. Symonds joined as chairperson of Innocoll’s board in May 2014. Mr. Symonds has been a director of HSBC Holdings plc since April 2014 and chairman of HSBC Bank plc since April 2014. Since October 2013, Mr. Symonds has served as an independent director and chairman of the audit committee of Genomics England Limited, and since June 2014 he has served as an independent director Proteus Digital Health, Inc. Mr. Symonds was appointed Commander of the British Empire (CBE) for services to business and the pharmaceutical industry in January 2007. Mr. Symonds was previously chief financial officer of Novartis AG from 2009 to 2013. Prior to joining Novartis, he was a partner and managing director of Goldman Sachs from 2007 to 2009, chief financial officer of AstraZeneca plc from 1997 to 2007 and a partner of KPMG from 1992 to 1997. Mr. Symonds has previously served on the board of directors of Diageo plc and Qinetiq plc. Mr. Symonds received a B.A. in Business Finance from the University of Hertfordshire, where he also received an honorary doctorate.
Shumeet Banerji, Ph.D
Vice-Chairperson
Dr. Banerji joined Innocoll’s board in May 2014. Dr. Banerji is co-founder and partner of Condorcet, LP, a private investment and advisory firm. He was the founding chief executive officer of Booz & Company, a global management consulting firm, from 2008 to 2012 and served as a senior partner from May 2012 to March 2013. Prior to that, he held multiple roles at Booz Allen Hamilton, a consulting company and predecessor to Booz & Company, including president of the worldwide commercial business, managing director, Europe, and managing director, United Kingdom. He was elected every year for 10 years to the firm’s Board of Directors. Dr. Banerji has been a director of the Hewlett-Packard Company since January 2011. Dr. Banerji received his Ph.D. from Northwestern University, Kellogg School of Management.
David R. Brennan
Mr Brennan joined our advisory board in May 2014. Mr. Brennan has nearly 40 years’ experience in the pharmaceutical industry. Mr. Brennan served as the chief executive officer of AstraZeneca Plc from January 2006 to June 2012, president and chief executive officer of AstraZeneca Pharmaceuticals LP from 2001−05, president and chief executive officer of AstraZeneca's North American subsidiary from 2001 to 2006, executive vice president of North America Division of AstraZeneca Plc from 2001 to 2005 and senior vice president of commercialization and portfolio management of AstraZeneca from 1998−2000. Prior to the merger between Astra AB and Zeneca Plc, Mr. Brennan served as senior vice president of business planning and development of Astra Pharmaceuticals LP, the American subsidiary of Astra AB. Mr. Brennan has been a director of the Chief Executive Officer Roundtable on Cancer since 2010 and a director of Insmed Incorporated since May 2014. Mr. Brennan served as an executive director of AstraZeneca Plc from 2005 to 2012, chairman of the board for the Southeastern Pennsylvania Chapter of the American Heart Association from 2004 to 2006, an executive board member of the Pharmaceutical Research and Manufacturers of America from 2001−12 and chairman from 2009−10, a member of the executive board and board member of the European Federation for Pharmaceutical Industries and Associations from 2006−12, president of the International Federation of Pharmaceutical Manufacturers and Associations from 2010−12, a member of the European Roundtable of Industrialists from 2006−12 and a member of the National Institute of Health Roundtable on Evidence Based Medicine from 2006−11. He was a participant and member of the International Business Council of the World Economic Forum. Mr. Brennan holds a B.A. in Business Administration from Gettysburg College, where he currently serves on the board of trustees.
James Culverwell
Mr. Culverwell has been a member of our advisory board, the predecessor to our supervisory board, since August 2013. Mr. Culverwell also served on Innocoll Holdings’ board of directors from December 2012 to August 2013. Mr. Culverwell has over 30 years’ experience in the pharmaceutical industry in pharmaceutical company analysis, investment banking and healthcare private equity. Mr. Culverwell joined Hoare Govett in 1982, where he became director of European healthcare research. He joined Merrill Lynch & Co. in 1995, where he became head of European pharmaceutical research and global coordinator for healthcare research and established a top-rated franchise. In 2004, Mr. Culverwell set up Sudbrook Associates, a healthcare corporate advisor specializing in fund raising, corporate advice and due diligence in the private healthcare sector. Mr. Culverwell also sits on the boards of four other companies in the specialty pharmaceutical, drug development and diagnostic field. Mr. Culverwell received a MSc from the University of Aberdeen.
Anthony H. Wild, Ph.D
Dr. Wild joined Innocoll’s board in July 2008 and acted as chairperson from 2010 until May 2014. Dr. Wild has over 40 years’ experience working in the pharmaceutical industry in Europe, Japan and the U.S. He has held senior positions in Warner Lambert’s Parke-Davis division, Schering Plough and MedPointe Pharmaceuticals. Dr. Wild founded Pilatus Venture Capital LLC, which invests in privately-owned healthcare businesses. In connection with these investments, he is currently Chairperson of Sprout Pharmaceuticals Inc., and is a member of the boards of directors of several other privately-owned specialty pharmaceutical and biotechnology companies. He also serves on the boards of advisors of Ferrer, Freeman and Co., a healthcare private equity firm and of Auven Therapeutics, a pharmaceutical venture fund. Dr. Wild received an honors degree in Chemistry from the University of York and a Ph.D. in Physical Chemistry from the University of Cambridge (Churchill College).
Rolf D. Schmidt
Mr. Schmidt has been a member of Innocoll's since 1997, and served as chairperson from 1997 - 2010. Mr. Schmidt was a co-founder of the medical bio-adhesives product company, Closure Medical Corporation. Mr. Schmidt led the company as chairperson from its early development through its initial public offering in 1996 and until its acquisition by Johnson & Johnson in 2005. He was co-founder of Sharpoint, Inc., a leading developer and manufacturer of ophthalmic surgical needles and sutures prior to its acquisition by Alcon Labs, Inc. in 1986. Mr. Schmidt actively consults with and invests in early-stage healthcare technology companies.
Management Board
Michael Myers, CHAIRMAN
Michael Myers, Ph.D. became president and chief executive officer and a member of the board of directors of Innocoll in June 2003. Dr. Myers has more than 27 years' of industry experience in the drug delivery and specialty pharmaceutical sectors. He has served as president of the drug delivery division of West Pharmaceutical Services, president of pharmaceutical operations for Fuisz Technologies (Biovail) and has held executive positions in Flamel Technologies and Elan Corporation. Dr. Myers earned his Ph.D. in Chemistry from the University College Cork.
Gordon Dunn
Gordon Dunn has served as chief financial officer since 2012. Prior to joining Innocoll, Mr. Dunn served on Innocoll’s board of directors as representative of NewSmith from December 2007 to December 2012. Mr. Dunn has 20 years’ experience in investment banking and private equity. Mr. Dunn has managed the private equity funds of NewSmith since their inception in 2004. Prior to joining NewSmith Capital, Mr. Dunn was employed in the investment banking and securities industry, including nine years at Merrill Lynch in London. At Merrill Lynch, Mr. Dunn held several senior positions, including co-head of the european private equity group and director of equity capital markets. Mr. Dunn began his career as an associate at the law firm of Morrison & Foerster LLP. He received a B.A. from Stanford University and a J.D. from New York University School of Law
